StockData
MannKind Corp logo

MannKind Corp (MNKD) company profile

MNKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30127% above fair value
$4.07+0.12 (+2.91%)

Close on Nov 17, 2026Market cap $1.31BP/E –Yield –

About MannKind

Pharmaceutical Preparations, SIC 2834

The company develops, manufactures, and commercializes therapeutic products and drug delivery systems for patient care. Its product portfolio includes Afrezza, Tyvaso DPI, V-Go, and Furoscix, alongside an on-body infusor technology and inhaled insulin formulations. In addition to commercial product sales, the enterprise provides contract manufacturing, development, and commercial supply services, and licenses its proprietary technologies. Its operations serve pharmaceutical and healthcare partners, with key collaborations and agreements involving United Therapeutics Corporation, Cipla, scPharmaceuticals, and Amphastar.

The entity conducts operations across several locations, maintaining business activities and leased properties in Connecticut and Minnesota, as well as facilities in Marlborough and on Russell Ranch Road. Internationally, commercial arrangements and distribution licensing relationships extend to India. The enterprise operates across these regional sites to support research, commercial manufacturing, and collaborative pharmaceutical distribution.

Summary of the business section of MannKind's latest annual report, written by StockData.

Company profile

Company

Legal name
MannKind Corp
Founded
1991
Headquarters
Danbury, CT
Address
1 Casper Street 06810
Phone
(818) 661-5000
Employees
241, Dec 31, 2020
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, Los Angeles, California

Stock & identifiers

Ticker
MNKD
Exchange
Nasdaq
IPO date
Jul 28, 2004
Shares outstanding
322M, Jul 24, 2026
Public float
$1.13B, Jun 30, 2025
Filer category
Large accelerated filer
Stock splits
1-for-5 reverse, Mar 3, 2017
SEC CIK
899460
CUSIP
56400P706
ISIN
US56400P7069
FIGI
BBG000PPL3G9
Share class FIGI
BBG001SLLLY3
LEI
213800GFBCNY1ZFST722
EIN
13-3607736

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Michael CastagnaChief Executive Officer, Director2,494,183
David ThomsonEVP Genl Counsel & Secretary797,554
Christopher B. PrentissChief Financial Officer318,668
Sanjay R. SinghEVP Technical Operations478,966
Stuart A. TrossChief People & Workpl Officer1,123,950
Dominic MarascoPres, Endocrine Business Unit343,398
Ajay AhujaChief Medical Officer318,200
Burkhard BlankEVP Chief Medical Officer460,791
Lauren M. SabellaEVP Operations349,841
Steven B. BinderDirector713,258
James Samuel ShannonDirector36,458
Christine MundkurDirector27,675
Jennifer GrancioDirector110,701
Sabrina KayDirector107,033
Michael A. FriedmanDirector86,700
Ronald J. ConsiglioDirector132,342
Anthony C. HooperDirector236,153

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$9.30M$752.39K$3.99M$181$125
FY2024$9.49M$22.84M$2.89M$205$93
FY2023$7.07M$96.76K$2.20M$116$94
FY2022$3.91M$9.65M$1.48M$168$90
FY2021$4.03M$7.32M$1.73M$140$100
FY2020$3.56M$7.42M$1.61M$243$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payOtherTotalvs. prior year
Michael E. Castagna
Chief Executive Officer
$789.44K$7.69M$675.76K$145.81K$9.30M-2%
Christopher B. Prentiss
Chief Financial Officer
$470.09K$2.13M$251.50K$31.74K$2.89M-14%
Dominic Marasco
President, Endocrine Business Unit
$447.60K$6.27M$239.46K$24.40K$6.98M–
David B. Thomson
EVP, General Counsel and Secretary
$520.75K$2.13M$378.60K$122.42K$3.16M+3%
Stuart A. Tross
EVP, Human Resources
$438.71K$2.13M$234.71K$138.80K$2.95M+0%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2020, we had 241 total employees, of which 240 were full-time.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?